Blocking aldosterone in heart failure

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 5, 2009, Pages 379-385

  Shafiq, Moiz M ^a   Miller, Alan B ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

Aldosterone; Aldosterone antagonism; Cardiac fibrosis; Heart failure

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; CARDIOVASCULAR AGENTS; DRUG THERAPY, COMBINATION; FIBROSIS; HEART FAILURE; HUMANS; MYOCARDIUM; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANRENONE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PERINDOPRIL; PLACEBO; RENIN INHIBITOR; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FIBRINOLYTIC THERAPY; FOOD INTAKE; GYNECOMASTIA; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT;

EID: 70350028719     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709341300     Document Type: Review

References (46)

1. Boccanelli, A., Mureddu, G.F., Cacciatore, G., Clemenza, F., Di Lenarda, A., Gavazzi, A. et al. (2009) Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 11: 68-76.
2. Brilla, C.G., Pick, R., Tan, L.B., Janicki, J.S. and Weber, K.T. ( 1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355-1364.
3. Brilla, C.G., Matsubara, L.S. and Weber, K.T. ( 1993) Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25: 563-575.
4. Brilla, C.G., Zhou, G., Matsubara, L. and Weber, K.T. ( 1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26: 809-820.
5. Callera, G.E., Touyz, R.M., Tostes, R.C., Yogi, A., He, Y., Malkinson, S. et al. (2005 a) Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45: 773-779.
6. Callera, G.E., Montezano, A.C., Yogi, A., Tostes, R.C., He, Y., Schiffrin, E.L. et al. (2005 b) c-Srcdependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 46: 1032-1038.
7. Campese, V.M., Ye, S., Zhong, H., Yanamadala, V., Ye, Z. and Chiu, J. ( 2004) Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 287: H695-H703.
8. Campese, V.M., Shaohua, Y. and Huiquin, Z. ( 2005) Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 46: 533-539.
9. Cleland, J.G., Tendera, M., Adamus, J., Freemantle, N., Polonski, L., Taylor, J. et al. (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27: 2338-2345.
10. Cohn, J.N. and Colucci, W. ( 2006) Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 97: 4F-12F.
11. CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435.
12. Dai, Q., Xu, M., Yao, M. and Sun, B. ( 2007) Angiotensin AT 1 receptor antagonists exert antiinflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 152: 1042-1048.
13. Francis, G.S., Benedict, C., Johnstone, D.E., Kirlin, P.C., Nicklas, J., Liang, C.S. et al. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82: 1724-1729.
14. Grandi, A.M., Imperiale, D., Santillo, R., Barlocco, E., Bertolini, A., Guasti, L. et al. (2002) Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 40: 647-652.
15. Hayashida, W., Donckier, J., van Mechelen, H., Charlier, A.A. and Pouleur, H. ( 1997) Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Cardiovasc Res 33: 54-62.
16. Juurlink, D.N., Mamdani, M.M., Lee, D.S., Kopp, A., Austin, P.C., Laupacis, A. et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551.
17. Kai, H., Kuwahara, F., Tokuda, K. and Imaizumi, T. ( 2005) Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28: 483-490.
18. Klug, D., Robert, V. and Swynghedauw, B. ( 1993) Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 71: 46A-54A.
19. Ko, D.T., Juurlink, D.N., Mamdani, M.M., You, J.J., Wang, J.T., Donovan, L.R. et al. (2006) Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. J Card Fail 12: 205-210.
20. Kuwahara, F., Kai, H., Tokuda, K., Kai, M., Takeshita, A., Egashira, K. et al. (2002) Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106: 130-135.
21. Lijnen, P. and Petrov, V. ( 2000) Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 32: 865-879.
22. Massie, B.M., Carson, P.E., McMurray, J.J., Komajda, M., McKelvie, R., Zile, M.R. et al. (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359: 2456-2467.
23. Monahan, K.D., Leuenberger, U.A. and Ray, C.A. ( 2007) Aldosterone impairs baroreflex sensitivity in healthy adults. Am J Physiol Heart Circ Physiol 292: H190-H197.
24. Overdiek, H.W. and Merkus, F.W. ( 1987) The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact 5: 273-302.
25. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A. et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709-717.
26. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B. et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321.
27. Pitt, B., White, H., Nicolau, J., Martinez, F., Gheorghiade, M., Aschermann, M. et al. (2005) Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46: 425-431.
28. Rajagopalan, S., Duquaine, D., King, S., Pitt, B. and Patel, P. ( 2002) Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 2212-2216.
29. Rocha, R., Rudolph, A.E., Frierdich, G.E., Nachowiak, D.A., Kekec, B.K., Blomme, E.A. et al. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283: H1802-H1810.
30. Sanderson, J.E. ( 2007) Heart failure with a normal ejection fraction. Heart 93: 155-158.
31. Sciarretta, S., Paneni, F., Palano, F., Chin, D., Tocci, G., Rubattu, S. et al. (2009) Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci 116: 467-477.
32. Sechi, L.A., Novello, M., Colussi, G., Di Fabio, A., Chiuch, A., Nadalini, E. et al. (2008) Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 21: 1347-1353.
33. Selye, H. ( 1949) The general adaptation syndrome and the diseases of adaptation. Practitioner 163: 393-405.
34. Selye, H. ( 1960) Protection by a steroid-spirolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med 104: 212-213.
35. Sun, Y., Zhang, J., Lu, L., Chen, S.S., Quinn, M.T. and Weber, K.T. ( 2002) Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol 161: 1773-1781.
36. Suzuki, G., Morita, H., Mishima, T., Sharov, V.G., Todor, A., Tanhehco, E.J. et al. (2002) Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106: 2967-2972.
37. Swedberg, K., Eneroth, P., Kjekshus, J. and Wilhelmsen, L. ( 1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82: 1730-1736.
38. Tokuda, K., Kai, H., Kuwahara, F. and Imaizumi, T. ( 2003) Sub-depressor dose of angiotensin type-1 receptor blocker inhibits transforming growth factor-beta-mediated perivascular fibrosis in hypertensive rat hearts. J Cardiovasc Pharmacol 42(Suppl. 1): S61-S65.
39. Wang, W. ( 1994) Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 24: 571-575.
40. Weber, K.T. and Brilla, C.G. ( 1991) Remodeling of the rat right and left ventricles in experimental hypertension. Circulation 83: 1849-1865.
41. Weintraub, W.S., Zhang, Z., Mahoney, E.M., Kolm, P., Spertus, J.A., Caro, J. et al. (2005) Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 111: 1106-1113.
42. Williams, J.S. and Williams, G.H. ( 2003) 50th anniversary of aldosterone. J Clin Endocrinol Metab 88: 2364-2372.
43. Yusuf, S., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J. et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777-781.
44. Zhang, Z.H., Yu, Y., Kang, Y.M., Wei, S.G. and Felder, R.B. ( 2008) Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 294: H1067-H1074.
45. Zile, M.R., Baicu, C.F. and Gaasch, W.H. ( 2004) Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350: 1953-1959.
46. Zillich, A.J. and Carter, B.L. ( 2002) Eplerenone - a novel selective aldosterone blocker. Ann Pharmacother 36: 1567-1576.